EB World Congress 2020
The first global congress on Epidermolysis Bullosa took place on 19-23 January, in London. ...
08 June, 2020
Research
11 June, 2018
First Patient Dosed with Dystrophic Epidermolysis Bullosa Treatment, KB103
Krystal Biotech have announced that the first patient has been dosed in the Phase 1/2 clinical trial of its drug, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). The Phase 1/2 trial at Stanford University is a single-centre, open-label, placebo-controlled study conducting an intra-subject comparison...
11 June, 2018
CU Anschutz scientists awarded $3.8 million Department of Defense grant
In 2016, together with two other US based medical research charities, we funded the EB iPS Cell Consortium, which includes researchers from leading universities in the US. The results of its early work were so promising that it leveraged a major grant of $3.8 million,...
18 December, 2015
BBC News – The promise of gene editing
Sharmila Nikapota, the mother of a child with a rare genetic disorder, has high hopes for gene editing...